SKLB 1028 - CSPC Ouyi PharmaceuticalAlternative Names: SKLB-1028
Latest Information Update: 11 Aug 2016
At a glance
- Originator CSPC Ouyi Pharmaceutical
- Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Epidermal growth factor inhibitors; Fms-like tyrosine kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia
Most Recent Events
- 01 May 2016 Phase-I clinical trials in Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in China (PO) (NCT02859948)